Edition:
United States

GlaxoSmithKline PLC (GSK.L)

GSK.L on London Stock Exchange

1,495.60GBp
6:01am EDT
Change (% chg)

1.40 (+0.09%)
Prev Close
1,494.20
Open
1,496.00
Day's High
1,502.20
Day's Low
1,488.40
Volume
3,078,204
Avg. Vol
9,035,314
52-wk High
1,724.50
52-wk Low
1,235.20

Chart for

About

GlaxoSmithKline plc is a global healthcare company. The Company operates through three segments: Pharmaceuticals, Vaccines and Consumer Healthcare. The Company focuses on its research across six areas: Respiratory diseases, human immunodeficiency virus (HIV)/infectious diseases, Vaccines, Immuno-inflammation, Oncology and Rare... (more)

Overall

Beta: 1.05
Market Cap(Mil.): £74,101.90
Shares Outstanding(Mil.): 4,959.30
Dividend: 19.00
Yield (%): --

Financials

  GSK.L Industry Sector
P/E (TTM): 34.87 28.26 32.60
EPS (TTM): 0.43 -- --
ROI: 8.95 13.20 12.74
ROE: 256.90 14.98 14.66

BRIEF-GlaxoSmithKline Says ViiV Granted EU Marketing Authorisation For Juluca

* VIIV HEALTHCARE RECEIVES EU MARKETING AUTHORISATION FOR JULUCA FIRST 2-DRUG REGIMEN, ONCE-DAILY, SINGLE-PILL FOR TREATMENT OF HIV Source text for Eikon: Further company coverage:

May 21 2018

BRIEF-GlaxoSmithKline Says Nucala Study Reports Long-Term Safety Data, Consistent Exacerbation Reduction, Improved Asthma Control

* NUCALA (MEPOLIZUMAB) STUDY REPORTS LONG-TERM SAFETY DATA, CONSISTENT EXACERBATION REDUCTION AND IMPROVED ASTHMA CONTROL

May 21 2018

Regulators flag possible birth defect link to GSK's HIV drug

LONDON U.S. and European regulators said they were assessing evidence that GlaxoSmithKline's HIV drug dolutegravir might be linked to serious birth defects, casting a shadow over a medicine that has been a key profit driver in recent years.

May 18 2018

UPDATE 1-Regulators flag possible birth defect link to GSK's HIV drug

LONDON, May 18 U.S. and European regulators said they were assessing evidence that GlaxoSmithKline's HIV drug dolutegravir might be linked to serious birth defects, casting a shadow over a medicine that has been a key profit driver in recent years.

May 18 2018

EU warns of possible birth defect link to GSK's HIV drug

LONDON, May 18 Europe's medicines regulator said it was assessing evidence that GlaxoSmithKline's successful HIV drug dolutegravir might be linked to birth defects, adding it should not be prescribed to women seeking to become pregnant.

May 18 2018

GSK bets on lift from new lung drugs ahead of Advair's last gasp

LONDON, May 18 GlaxoSmithKline is putting more marketing muscle behind its new lung drugs and is looking for a sales boost as top respiratory experts gather to analyse clinical trials data at a meeting in San Diego this weekend.

May 17 2018

Drugmaker GSK rings in more change as CFO heads for exit in 2019

LONDON GlaxoSmithKline Plc , Britain's biggest drugmaker, faces more top management change with Chief Financial Officer Simon Dingemans set to retire next year.

May 09 2018

UPDATE 1-Drugmaker GSK rings in more change as CFO heads for exit in 2019

LONDON, May 9 GlaxoSmithKline Plc, Britain's biggest drugmaker, faces more top management change with Chief Financial Officer Simon Dingemans set to retire next year.

May 09 2018

GlaxoSmithKline CFO Dingemans to retire in 2019

May 9 GlaxoSmithKline Plc chief financial officer Simon Dingemans has decided to retire, the company said on Wednesday.

May 09 2018

BRIEF-GlaxoSmithKline CFO Simon Dingemans To Retire From Company

* SIMON DINGEMANS, CHIEF FINANCIAL OFFICER (CFO), GSK, HAS INFORMED BOARD OF HIS INTENTION TO RETIRE FROM COMPANY

May 09 2018

Earnings vs. Estimates